{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106228","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.734266+00:00","generated_at":"2026-05-17T15:48:15.430907+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apogee reports positive APG777 Phase 2 data and Q2 net loss of $66.1M","bullets":["APG777 APEX Part A met primary endpoint: 71.0% EASI reduction vs 33.8% placebo (p<0.001).","Cash, cash equivalents and marketable securities at $621.2M as of June 30, 2025; runway into Q1 2028.","Net loss of $66.1M for Q2 2025, up from $33.8M in Q2 2024, driven by higher R&D expenses.","Phase 2 Part B readout accelerated to mid-2026; Phase 3 plans on track for 2026.","First patient dosed in Phase 1b combination trial of APG279 vs DUPIXENT in atopic dermatitis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106228","json":"https://secwatch.observer/filing/0000950170-25-106228.json","markdown":"https://secwatch.observer/filing/0000950170-25-106228.md","text":"https://secwatch.observer/filing/0000950170-25-106228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/0000950170-25-106228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:48:15.430907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}